

Message

From: Devarakonda, Krishna [Devarakonda, Krishna]
Sent: 8/13/2010 3:37:33 AM
To: Giuliani, Michael
CC: Heasley, Ralph A; Young, Jim L; Pierro, Joseph A; Coulson, Karen E; Herman, Cliff; Shelby, Susan ; Gupta, Vishal; Agarwal, Shefali; Matchett, Mike; Fletcher, Mickey ; Ross, Chip
Attachments: Zircon and Ruby Strengths.docx

Dr. Giuliani,

The members of senior management (Ralph, Jim & Joe) and team leaders of Zircon & Ruby met this afternoon and discussed different combination strengths of HB/APAP (Zircon) and OC/APAP (Ruby) formulations compared to approved RLD formulations (Orange Book listings) in terms of opioid/APAP ratio as well as total 12hr APAP exposure (Please see the attached tables).

For both Zircon & Ruby formulations the 15/650 combination satisfies the above two criteria. Our dosage recommendation will be one/two tablet(s) q12h.

In case of Zircon the strength 15/650 q12h corresponds to the RLD 7.5/325 dosed q6h instead of q4h (per labeled dosing recommendation). We will be using Norco 7.5/325 q6h for our PK comparisons.

In case of Ruby this combination matches with Percocet 7.5/325 q6h, which we are already using as our LD in our PK studies.

Both Zircon and Ruby project team leaders approved this approach and recommended a review on the combination guidance by Hyman Phelps.

Please let me know if you have additional questions or need additional information.

Regards. Krishna